Caricamento...
Pioglitazone and cardiovascular risk reduction: time for a second look?
Insulin resistance, a fundamental pathophysiological abnormality in patients with type 2 diabetes, is associated with increased cardiovascular (CV) disease risk. In diabetes management, the macrovascular impact of antihyperglycemic agents that do not improve insulin sensitivity has generally been di...
Salvato in:
| Pubblicato in: | Cardiovasc Endocrinol |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Wolters Kluwer Health
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6768516/ https://ncbi.nlm.nih.gov/pubmed/31646121 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/XCE.0000000000000110 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|